Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Fig. 3

Spider plot of tumor diameter dynamics during PD-1/PD-L1 inhibitor therapy in 75 patients with measurable lesions. During the follow-up, patients with tumor diameter that maintained a < 20% increase from baseline were classified as the treatment benefit group (n = 48; tumor diameter maintained a < 20% increase in those patients)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us